Trimetazidine for improving blood flow in transthyretin cardiac amyloidosis
Part of Heart & circulation clinical trials.
This study tests a medication called trimetazidine to see if it improves blood flow in the heart for people with transthyretin cardiac amyloidosis. It may help improve symptoms like shortness of breath and fatigue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of transthyretin cardiac amyloidosis (a condition where abnormal proteins build up in the heart).
- You must be over 18 years old.
- You must have symptoms of heart failure (like shortness of breath or fatigue) and be in functional class II, III, or IV.
- You must not have a known allergy or bad reaction to trimetazidine.
- You must not be taking certain heart medications (calcium channel blockers, beta-blockers, or nitrates).
- You must not have significant blockages in your heart arteries or severe kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study tests a new type of heart imaging scan called [68Ga]Ga-FAPI-46 PET to help doctors see and track transthyretin cardiac amyloidosis (a disease where abnormal proteins damage the heart). The scan may help identify which patients are getting worse.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
This study tests a new PET imaging agent (evuzamitide) to see if it can better detect cardiac amyloidosis when earlier tests were unclear. It may help confirm if the heart problem is related to TTR amyloid and guide further care.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Hear when a new Transthyretin Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.